• Je něco špatně v tomto záznamu ?

Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity

Trávnícek Z, Krystof V, Sipl M.

. 2006 ; 100 (2) : 214-225.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc07520029

The synthesis, characterization and biological activity of the first zinc(II) complexes with potent inhibitors of cyclin-dependent kinases (CDKs) derived from 6-benzylaminopurine are described. Based on the results following from elemental analyses, infrared, NMR and ES+MS (electrospray mass spectra in the positive ion mode) spectroscopies, conductivity data, thermal analysis and X-ray structures, the tetrahedral Zn(II) complexes of the compositions [Zn(Olo)Cl(2)](n) (1), [Zn(iprOlo)Cl(2)](n) (2), [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been prepared, where Olo=2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine (Olomoucine), iprOlo=2-(2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (i-propyl-Olomoucine), Boh=2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine (Bohemine). The 1D-polymeric chain structure for [Zn(Olo)Cl(2)](n) (1) as well as the monomeric one for [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been revealed unambiguously by single crystal X-ray analyses. The 1D-polymeric chain of 1 consists of Zn(Olo)Cl(2) monomeric units in which the Zn(II) ion is coordinated by two chlorine atoms and one oxygen atom of the 2-hydroxyethylamino group of Olomoucine. The next monomeric unit is bonded to Zn(II) through the N7 atom of a purine ring. Thus, each of Zn(II) ions is tetrahedrally coordinated and a ZnCl(2)NO chromophore occurs in the complex 1. The complexes 3 and 4 are mononuclear species with a distorted tetrahedral arrangement of donor atoms around the Zn(II) ion with a ZnCl(3)N chromophore. The corresponding CDK inhibitor, i.e., both Boh and iprOlo, is coordinated to Zn(II) via the N7 atom of the purine ring in 3 and 4. The cytotoxicity of the zinc(II) complexes against human melanoma, sarcoma, leukaemia and carcinoma cell lines has been determined as well as the inhibition of the CDK2/cyclin E kinase. A relationship between the structure and biological activity of the complexes is also discussed.

000      
00000naa 2200000 a 4500
001      
bmc07520029
003      
CZ-PrNML
005      
20111210130959.0
008      
090325s2006 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Trávníček, Zdeněk, $d 1964- $7 ola2004209199
245    10
$a Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity / $c Trávnícek Z, Krystof V, Sipl M.
314    __
$a Department of Inorganic Chemistry, Palacký University, Krízkovského 10, CZ-771 47 Olomouc, Czech Republic. trav@aix.upol.cz
520    9_
$a The synthesis, characterization and biological activity of the first zinc(II) complexes with potent inhibitors of cyclin-dependent kinases (CDKs) derived from 6-benzylaminopurine are described. Based on the results following from elemental analyses, infrared, NMR and ES+MS (electrospray mass spectra in the positive ion mode) spectroscopies, conductivity data, thermal analysis and X-ray structures, the tetrahedral Zn(II) complexes of the compositions [Zn(Olo)Cl(2)](n) (1), [Zn(iprOlo)Cl(2)](n) (2), [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been prepared, where Olo=2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine (Olomoucine), iprOlo=2-(2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (i-propyl-Olomoucine), Boh=2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine (Bohemine). The 1D-polymeric chain structure for [Zn(Olo)Cl(2)](n) (1) as well as the monomeric one for [Zn(BohH(+))Cl(3)] x H(2)O (3) and [Zn(iprOloH(+))Cl(3)] x H(2)O (4) have been revealed unambiguously by single crystal X-ray analyses. The 1D-polymeric chain of 1 consists of Zn(Olo)Cl(2) monomeric units in which the Zn(II) ion is coordinated by two chlorine atoms and one oxygen atom of the 2-hydroxyethylamino group of Olomoucine. The next monomeric unit is bonded to Zn(II) through the N7 atom of a purine ring. Thus, each of Zn(II) ions is tetrahedrally coordinated and a ZnCl(2)NO chromophore occurs in the complex 1. The complexes 3 and 4 are mononuclear species with a distorted tetrahedral arrangement of donor atoms around the Zn(II) ion with a ZnCl(3)N chromophore. The corresponding CDK inhibitor, i.e., both Boh and iprOlo, is coordinated to Zn(II) via the N7 atom of the purine ring in 3 and 4. The cytotoxicity of the zinc(II) complexes against human melanoma, sarcoma, leukaemia and carcinoma cell lines has been determined as well as the inhibition of the CDK2/cyclin E kinase. A relationship between the structure and biological activity of the complexes is also discussed.
650    _2
$a protinádorové látky $x farmakologie $x chemie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a chloridy $x farmakologie $x chemie $7 D002712
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a cyklin-dependentní kinasy $x antagonisté a inhibitory $x chemie $7 D018844
650    _2
$a diferenční termická analýza $7 D004055
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a inhibitory enzymů $x farmakologie $x chemická syntéza $x chemie $7 D004791
650    _2
$a kinetin $x farmakologie $x chemie $7 D007701
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a magnetická rezonanční spektroskopie $7 D009682
650    _2
$a hmotnostní spektrometrie $7 D013058
650    _2
$a molekulární struktura $7 D015394
650    _2
$a organokovové sloučeniny $x farmakologie $x chemická syntéza $x chemie $7 D009942
650    _2
$a puriny $x farmakologie $x chemie $7 D011687
650    _2
$a spektrofotometrie infračervená $7 D013055
650    _2
$a sloučeniny zinku $x farmakologie $x chemie $7 D017967
650    _2
$a financování organizované $7 D005381
700    1_
$a Kryštof, Vladimír, $d 1973- $7 xx0097406
700    1_
$a Šipl, Michal. $7 xx0222464
773    0_
$w MED00006646 $t Journal of inorganic biochemistry $g Roč. 100, č. 2 (2006), s. 214-225 $x 0162-0134
910    __
$a ABA008 $b x $y 9
990    __
$a 20090325104238 $b ABA008
991    __
$a 20090630141656 $b ABA008
999    __
$a ok $b bmc $g 637833 $s 490629
BAS    __
$a 3
BMC    __
$a 2006 $b 100 $c 2 $d 214-225 $i 0162-0134 $m Journal of inorganic biochemistry $x MED00006646
LZP    __
$a 2009-B1/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...